11:05 AM EDT, 06/17/2024 (MT Newswires) -- TPG (TPG) said Monday it made a "significant" strategic growth investment in K2 Medical Research, a clinical trial site platform that focuses on central nervous system trials for pharmaceutical and biotech sponsors.

Terms of the deal weren't provided.

K2, which operates clinical trial sites in Florida, specializes in conducting multi-phase clinical trials in therapeutic areas including Alzheimer's, psychiatry, and liver disease, among others trials, TPG said.

Price: 40.33, Change: -0.44, Percent Change: -1.08